Bank of New York Mellon’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-133,680
| Closed | -$247K | – | 4523 |
|
|
2023
Q1 | $247K | Hold |
133,680
| – | – | ﹤0.01% | 3831 |
|
|
2022
Q4 | $148K | Sell |
133,680
-11,020
| -8% | -$15.7K | ﹤0.01% | 4057 |
|
|
2022
Q3 | $339K | Buy |
144,700
+18,290
| +14% | +$64.8K | ﹤0.01% | 3771 |
|
|
2022
Q2 | $383K | Sell |
126,410
-842
| -0.7% | -$4.09K | ﹤0.01% | 3752 |
|
|
2022
Q1 | $865K | Buy |
127,252
+247
| +0.2% | +$1.76K | ﹤0.01% | 3403 |
|
|
2021
Q4 | $1.06M | Sell |
127,005
-1,074
| -0.8% | -$8.85K | ﹤0.01% | 3346 |
|
|
2021
Q3 | $952K | Buy |
128,079
+25,811
| +25% | +$160K | ﹤0.01% | 3423 |
|
|
2021
Q2 | $695K | Buy |
102,268
+31,097
| +44% | +$258K | ﹤0.01% | 3613 |
|
|
2021
Q1 | $731K | Sell |
71,171
-869
| -1% | -$9.52K | ﹤0.01% | 3499 |
|
|
2020
Q4 | $504K | Sell |
72,040
-114,247
| -61% | -$889K | ﹤0.01% | 3614 |
|
|
2020
Q3 | $1.52M | Sell |
186,287
-14,363
| -7% | -$89.1K | ﹤0.01% | 2846 |
|
|
2020
Q2 | $1.39M | Sell |
200,650
-8,357
| -4% | -$45.1K | ﹤0.01% | 2909 |
|
|
2020
Q1 | $993K | Sell |
209,007
-11,124
| -5% | -$64K | ﹤0.01% | 2988 |
|
|
2019
Q4 | $1.92M | Buy |
220,131
+134,965
| +158% | +$729K | ﹤0.01% | 2841 |
|
|
2019
Q3 | $284K | Buy |
85,166
+145
| +0.2% | +$580 | ﹤0.01% | 3798 |
|
|
2019
Q2 | $421K | Buy |
85,021
+17,218
| +25% | +$91.4K | ﹤0.01% | 3681 |
|
|
2019
Q1 | $420K | Sell |
67,803
-1,265
| -2% | -$6.11K | ﹤0.01% | 3626 |
|
|
2018
Q4 | $233K | Buy |
69,068
+21,475
| +45% | +$100K | ﹤0.01% | 3804 |
|
|
2018
Q3 | $309K | Buy |
47,593
+25
| +0.1% | +$186 | ﹤0.01% | 3817 |
|
|
2018
Q2 | $365K | Sell |
47,568
-1,072
| -2% | -$15.5K | ﹤0.01% | 3772 |
|
|
2018
Q1 | $1.09M | Buy |
48,640
+2,751
| +6% | +$61.1K | ﹤0.01% | 3172 |
|
|
2017
Q4 | $585K | Buy |
45,889
+4,467
| +11% | +$65.7K | ﹤0.01% | 3540 |
|
|
2017
Q3 | $646K | Buy |
41,422
+15,848
| +62% | +$224K | ﹤0.01% | 3459 |
|
|
2017
Q2 | $359K | Buy |
25,574
+8,063
| +46% | +$173K | ﹤0.01% | 3745 |
|
|
2017
Q1 | $385K | Buy |
+17,511
| New | +$371K | ﹤0.01% | 3660 |
|
Other funds holding JNCE
Bank of New York Mellon's JNCE Position: Q2 2023 in Review
Bank of New York Mellon sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 133,680 shares — an estimated $247K sold.
Bank of New York Mellon first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $1.92M in Q4 2019. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Bank of New York Mellon reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Bank of New York Mellon sold 133,680 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $247K.
- Bank of New York Mellon first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- Bank of New York Mellon's Jounce Therapeutics, Inc. Common Stock position peaked at $1.92M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Bank of New York Mellon's 13F filing for Q2 2023, filed 3 Aug 2023.